Bivalirudin Powder ≥98% CAS No: 128270-60-0
Bivalirudin Powder ≥98% CAS No: 128270-60-0
CAS No: 128270-60-0,Bivalirudin Powder ≥98% ,Bivalirudin Powder CAS No: 128270-60-0,Bivalirudin Powder,Bivalirudin,Bivalirudin research reagent,High purity Bivalirudin powder,Thrombin research compound,Pharmaceutical research powder
Product Name: Bivalirudin API Powder
Product purity: ≥98%
CAS No: 128270-60-0
Send Inquiry
Description
High Purity ≥98% | HPLC Validated
Bivalirudin Research Reagent
Direct Thrombin Inhibitor (DTI) for Advanced Hemostasis & Thrombosis Research
ATTENTION:
This product is a highly purified synthetic peptide intended strictly for Laboratory R&D use only. It is NOT a clinical drug and must not be used for human or veterinary administration. Shaanxi Sunrise Pharmaceutical Co., Ltd. bears no responsibility for unauthorized clinical applications.
Product Detailed Description
Bivalirudin is a synthetic, highly specific 20-amino acid peptide that serves as a reversible Direct Thrombin Inhibitor (DTI). Unlike indirect inhibitors like heparin, our research-grade Bivalirudin interacts directly with the thrombin molecule without requiring the presence of antithrombin III as a cofactor.
Designed for precision research, this reagent provides a predictable anticoagulation response in experimental models. It is an essential tool for labs studying coronary interventions, extracorporeal circulation systems, and heparin-induced thrombocytopenia (HIT) simulation models.
Advanced Mechanism of Action
Bivalent Binding Interaction
In academic research models, Bivalirudin exhibits a unique "dual-site" binding mechanism:
Active Site Binding: The N-terminal D-Phe-Pro-Arg-Pro sequence binds to the catalytic site of thrombin, immediately blocking its enzymatic activity.
Exosite-1 Binding: The C-terminal dodecapeptide sequence (analogous to the C-terminus of hirudin) binds to the anion-binding exosite I of thrombin.
Self-Limiting Advantage: Once bound, thrombin slowly cleaves the Arg₃-Pro₄ bond of Bivalirudin, which facilitates the eventual recovery of thrombin function. This "reversible" nature is a primary subject of study in reducing experimental bleeding complications.
Research Application Comparison
Bivalirudin is frequently compared to Unfractionated Heparin (UFH) in laboratory settings to evaluate safety margins and efficacy in high-risk models.
| Research Metric | Bivalirudin (Sunrise Grade) | Heparin (UFH) Reference |
|---|---|---|
| Inhibition Type | Direct (Free & Fibrin-bound) | Indirect (Free Thrombin only) |
| Cofactor Dependency | None (ATIII-Independent) | Requires Antithrombin III |
| Half-life (Simulated) | ~25 mins (Predictable) | 60-90 mins (Variable) |
| Platelet Interaction | No HIT Risk in models | Potential for HIT induction |
| ACT Monitoring | Linear correlation | Non-linear / Unpredictable |
Specialized R&D Scenarios
ECMO Anticoagulation Models: Recent literature (2025-2026) suggests Bivalirudin as a critical reference for reducing thrombotic events in experimental extracorporeal circuits compared to heparin.
Renal Impairment Simulations: Researching dose-response curves where renal clearance is modified, as Bivalirudin clearance is partially dependent on proteolytic degradation.
Surface Coating Research: Evaluating the immobilization of Bivalirudin on stent or catheter surfaces to improve biocompatibility.
Procurement FAQ
Q: Is the HPLC spectrum available?
A: Yes. Each shipment from Shaanxi Sunrise includes a batch-specific COA including HPLC and Mass Spec data for research validation.
Q: Can you provide bulk quantities for pilot formulation studies?
A: We support scale-up from milligram research samples to multi-kilogram batches for pharmaceutical R&D labs.